NCT00000958View on ClinicalTrials.gov

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1995

Conditions
HIV Infections
Interventions
BIOLOGICAL

MTP-PE/MF59

BIOLOGICAL

Env 2-3

Trial Locations (1)

14642

Univ. of Rochester AVEG, Rochester

Sponsors

Collaborators (1)

Biocine
All Listed Sponsors
collaborator

Biocine

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH